301301 川寧生物
按盤價 
8.530 +0.090 (+1.066%)
8.530 +0.090 (+1.066%) | 2026/03 - 三個月 | 2025/12 | 2024/12 | 2023/12 | 2022/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 1.361 | 9.625 | 18.849 | 14.289 | 7.499 |
| 總資產報酬率 ROA (%) | 1.063 | 7.330 | 13.535 | 9.163 | 4.146 |
| 投入資產回報率 ROIC (%) | 1.183 | 8.168 | 14.929 | 9.985 | 4.487 | 邊際利潤分析 |
| 銷售毛利率 (%) | 23.557 | 29.251 | 36.386 | 31.574 | 24.798 |
| 營業利潤率 (%) | 13.015 | 20.731 | 29.310 | 23.249 | 14.268 |
| 息稅前利潤/營業總收入 (%) | 13.906 | 20.994 | 29.930 | 24.434 | 15.983 |
| 淨利潤/營業總收入 (%) | 10.052 | 16.644 | 24.319 | 19.500 | 10.771 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 101.602 | 103.225 | 101.401 | 105.081 | 118.651 |
| 價值變動淨收益/利潤總額(%) | -1.988 | -0.612 | -0.547 | -1.318 | -1.837 |
| 營業外收支淨額/利潤總額(%) | -2.699 | -1.950 | -0.756 | -0.330 | -11.790 | 償債能力分析 |
| 流動比率 (X) | 2.569 | 2.413 | 2.128 | 1.560 | 1.672 |
| 速動比率 (X) | 1.759 | 1.553 | 1.439 | 0.899 | 1.161 |
| 資產負債率 (%) | 20.999 | 22.260 | 24.988 | 31.220 | 40.229 |
| 帶息債務/全部投入資本 (%) | 7.284 | 6.805 | 11.506 | 21.568 | 35.033 |
| 股東權益/帶息債務 (%) | 1,192.408 | 1,278.165 | 719.585 | 349.970 | 184.124 |
| 股東權益/負債合計 (%) | 375.088 | 348.135 | 299.473 | 219.900 | 148.436 |
| 利息保障倍數 (X) | 11.279 | 31.821 | 35.640 | 19.374 | 4.964 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 89.687 | 76.909 | 52.746 | 60.668 | 78.132 |
| 存貨周轉天數 (天) | 151.803 | 156.655 | 148.326 | 166.893 | 177.739 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 14/07/2026 11:58 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
